Voyager Therapeutics Inc (VYGR) Given Consensus Recommendation of “Buy” by Analysts
Voyager Therapeutics Inc (NASDAQ:VYGR) has been assigned an average recommendation of “Buy” from the sixteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.90.
Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Stifel Nicolaus restated a “buy” rating and issued a $31.00 price objective (up previously from $20.00) on shares of Voyager Therapeutics in a report on Monday, October 23rd. Raymond James Financial assumed coverage on Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 price objective for the company. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Finally, Robert W. Baird began coverage on Voyager Therapeutics in a report on Monday, October 30th. They set an “outperform” rating and a $31.00 target price for the company.
Shares of Voyager Therapeutics (VYGR) traded up $0.40 during trading on Tuesday, hitting $16.56. The stock had a trading volume of 180,774 shares, compared to its average volume of 323,133. The firm has a market capitalization of $435.50 and a price-to-earnings ratio of -5.83. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $25.99.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its position in Voyager Therapeutics by 312.8% during the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after buying an additional 285,806 shares during the period. Citadel Advisors LLC acquired a new position in Voyager Therapeutics during the third quarter valued at $5,155,000. DAFNA Capital Management LLC raised its position in Voyager Therapeutics by 187.2% during the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after buying an additional 133,488 shares during the period. Point72 Asset Management L.P. acquired a new position in Voyager Therapeutics during the third quarter valued at $2,695,000. Finally, Mckinley Capital Management LLC Delaware acquired a new position in Voyager Therapeutics during the third quarter valued at $1,412,000. 35.97% of the stock is owned by institutional investors and hedge funds.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.